Last updated on October 2018

Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia


Brief description of study

The primary objective of the study is to demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by evinacumab intravenously (IV) in comparison to placebo after 24 weeks in patients with homozygous familial hypercholesterolemia (HoFH). The secondary objectives of the study are to evaluate the effect of evinacumab IV on other lipid parameters, evaluate the effect of evinacumab on LDL-C goal attainment, assess the effect of evinacumab on eligibility for apheresis (using German and US apheresis criteria), evaluate the safety and tolerability of evinacumab in patients with HoFH, assess the pharmacokinetics (PK) of evinacumab in patients with HoFH and evaluate the potential development of anti-evinacumab antibodies.

Clinical Study Identifier: NCT03399786

Find a site near you

Start Over

Regeneron Research Site

Cape Town, South Africa
2.22miles
  Connect »